蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1903|回复: 2
收起左侧

转博客--FDA对医疗器械警告信进行分析

[复制链接]
药徒
发表于 2014-10-11 11:38:05 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
FDA analyses Warning Letters with regard to Medical Devices
FDA对医疗器械警告信进行分析
The ECA annually provides an analysis of the Warning Letters issued by the FDA with regard to medical devices. The analysis is based on the Warning Letters published over a fiscal year (from 1st October to 30 September). The FDA has published its own 2012 calendar year overview.
ECA每年都会提供一份对FDA关于医疗器械的警告信的分析。该分析是根据各财年公布的警告信所做的(从10月1日至9月30日)。FDA
刚公布了其自己对2012自然年所做的回顾。
Interestingly, the FDA says that it has made the results available for the industry to:
有意思的是,FDA说该回顾使得行业可以获得以下机会:
Improve the quality of medical devices
提高医疗器械的质量
Identify potential critical areas of manufacturers of medical devices
识别医疗器械生产商的潜在关键领域
Help companies avoid the reception of Warning Letters
帮助公司避免收到警告信
In 2012 the number of domestic routine FDA inspections at manufacturers of medical devices increased by 37%. For foreign companies it was a 93% increase.
在2012年,FDA所执行的本土医疗器械生产商检查数量增加了37%,对国外公司的检查数量则增加了93%。
In respectively 30% of the Forms 483 with inspection deficiencies, the CAPA system and insufficient production and process controls (incl. the process validation topic) have been criticised. Beside CAPA failures, the most frequent deficiencies observed in the FDA Forms 483 were "Complaint-Handling" (21 CFR 820.198a) and quality audits (21 CFR 820.22). Moreover, a significant increase with regard to "device history records" (21 CFR 820.184) was recorded in the Forms 483.
在FDA检查缺陷483表中,CAPA体系和生产及工艺控制不充分的缺陷各占了30%。除了CAPA方面的问题,FDA的483表中最常见的缺陷是“客诉投诉”(21 CFR 820.198a)和质量审计(21CFR 820.22)。另外,483表中“仪器历史记录”(21 CFR 820.198a)方面的缺陷有大幅增加。
According to the FDA, the number of Warning Letters (which are significantly more serious than a Form 483) has been increasing over the last 2 years because of the growing number of inspections. Consistent with the results of the Form 483, most of the deficiencies observed in the Warning Letters also concerned CAPA and "Complaint-Handling" topics. It is noticeable that two deficiencies are much more frequent in the Warning Letters than in the inspection results: these are deviations with regard to "device history records" (21 CFR 820.184) and process validation (21 CFR 820.75a).
根据FDA的数据,由于检查次数增加,在过去2年警告信(警告信比483表要严重的多)增加了。与483表的数量相称,大部分在警告信中出现的缺陷也是关于CAPA和“客诉-处理”问题的。值得注意的是两类缺陷在警告信中出现的频次高于检查的结果:与器具历史记录的缺失有关的偏差和工艺评估(21CFR 820.75a)。
Conclusion: The result coincides pretty well with the 2012 fiscal year evaluation by the ECA. The evaluation prepared by the ECA for 2012 refers to the fiscal year while the FDA used the calendar year for their evaluation. This explains the slight differences in the results.结论:结果与2012财处ECA所做的评估符合性很好。由ECA在2012年所做的评估是按财年统计的,而FDA使用的是自然年数据进行评估。这也就解释了为什么两者间有轻微的差异。
Please find more details in an FDA presentation.
更多信息参见FDA介绍。
回复

使用道具 举报

药徒
 楼主| 发表于 2014-10-11 11:39:09 | 显示全部楼层
The ECA annually provides an analysis of the Warning Letters issued by the FDA with regard to medical devices. The analysis is based on the Warning Letters published over a fiscal year (from 1st October to 30 September). The FDA has published its own 2012 calendar year overview.
Interestingly, the FDA says that it has made the results available for the industry to:
Improve the quality of medical devices
Identify potential critical areas of manufacturers of medical devices
Help companies avoid the reception of Warning Letters
In 2012 the number of domestic routine FDA inspections at manufacturers of medical devices increased by 37%. For foreign companies it was a 93% increase.
In respectively 30% of the Forms 483 with inspection deficiencies, the CAPA system and insufficient production and process controls (incl. the process validation topic) have been criticised. Beside CAPA failures, the most frequent deficiencies observed in the FDA Forms 483 were "Complaint-Handling" (21 CFR 820.198a) and quality audits (21 CFR 820.22). Moreover, a significant increase with regard to "device history records" (21 CFR 820.184) was recorded in the Forms 483.
According to the FDA, the number of Warning Letters (which are significantly more serious than a Form 483) has been increasing over the last 2 years because of the growing number of inspections. Consistent with the results of the Form 483, most of the deficiencies observed in the Warning Letters also concerned CAPA and "Complaint-Handling" topics. It is noticeable that two deficiencies are much more frequent in the Warning Letters than in the inspection results: these are deviations with regard to "device history records" (21 CFR 820.184) and process validation (21 CFR 820.75a).
Conclusion: The result coincides pretty well with the 2012 fiscal year evaluation by the ECA. The evaluation prepared by the ECA for 2012 refers to the fiscal year while the FDA used the calendar year for their evaluation. This explains the slight differences in the results.
Please find more details in an FDA presentation.
PS: All delegates of the ECA Education Course "GMP for Medical Devices" from 1-2 October 2014 in Heidelberg, Germany, will receive the FDA Medical Device Warning Letter Navigator on CD-ROM with the new Warning Letter results for the fiscal year 2014.
回复

使用道具 举报

药徒
发表于 2014-11-21 08:42:09 | 显示全部楼层
辛苦了,支持一下
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-2-23 17:36

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表